Table 2.
Patient demography and clinical presentation
| Characteristics | Values | Characteristics | Values |
|---|---|---|---|
| Age (years) | 76 (range 54–87) | Pre-treatment hormone treatment | |
| Gleason score | |||
| 1 + 3 | 1 (0.8%) | Yes | 36 (27.1%) |
| 3 + 2 | 2 (1.5%) | No | 97 (72.9%) |
| 3 + 3 | 41 (30.8%) | Stage | |
| 3 + 4 | 25 (18.8%) | T2a | 43 (32.3%) |
| 4 + 3 | 22 (16.5%) | T2b | 9 (6.8%) |
| 4 + 4 | 23 (17.3%) | T2c | 49 (36.8%) |
| 3 + 5 | 1 (0.8%) | T3a | 1 (0.8%) |
| 5 + 3 | 2 (1.5%) | T3b | 6 (4.5%) |
| 4 + 5 | 9 (6.8%) | T4 | 25 (18.8%) |
| 5 + 4 | 6 (4.5%) | Tx | 16 (12.0%) |
| 5 + 5 | 1 (0.8%) | NCCN risk grouping | |
| Median (interquartile range) PSA at diagnosis (ng/ml) | 15.98 (9.1–26.2) | Low | 10 (7.5%) |
| Pre-treatment PSA (ng/ml) | Favorable intermediate | 21 (15.8%) | |
| < 10 | 52 (39.1%) | Unfavorable intermediate | 31 (23.3%) |
| 10–20 | 47 (35.3%) | ||
| > 20 | 34 (25.6%) | High | 45 (33.8%) |
| Symptoms | |||
| Presented | 59 (44.4%) | Very high | 26 (19.5%) |
| None | 74 (55.6%) | Pre-treatment TURP | |
| ECOG score | Yes | 25 (18.8%) | |
| 0 | 5 (3.8%) | No | 108 (81.2%) |
| 1 | 128 (96.2%) |